KROS

Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors

Retrieved on: 
火曜日, 5月 28, 2024
Patient, BioMarin Pharmaceutical, Genentech, Economics, Tissue plasminogen activator, Retirement, KROS, Disorder, Protein, Strategic planning, Sanofi, University, Therapy, Senior, Growth, Cancer, Commerce, Worldwide, Business development, Biotechnology, Splenic infarction, Management

From November 2002 to April 2005, Mr. Bienaimé served as the Chairman, Chief Executive Officer and President of Genencor, Inc., a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics.

Key Points: 
  • From November 2002 to April 2005, Mr. Bienaimé served as the Chairman, Chief Executive Officer and President of Genencor, Inc., a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics.
  • Earlier in his career, Mr. Bienaimé worked at Genentech, Inc. where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks.
  • Mr. Bienaimé currently serves on the board of directors of Incyte Corporation and Immunome, Inc., as well as serving on the board of directors of a private biotechnology company.
  • Mr. Bienaimé received an M.B.A. from the Wharton School at the University of Pennsylvania and a degree in economics from the École Supérieure de Commerce de Paris.

Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association

Retrieved on: 
火曜日, 5月 14, 2024
IIA, Patient, Human, Anemia, KROS, Disorder, Protein, Therapy, EHA, Abstract, European Hematology Association, Facial muscles, Pharmaceutical industry

LEXINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that five abstracts will be presented from the KER-050 (elritercept) program at the 29th Annual Congress of the European Hematology Association (“EHA”), to be held both virtually and in person from June 13 through 16, 2024.

Key Points: 
  • LEXINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that five abstracts will be presented from the KER-050 (elritercept) program at the 29th Annual Congress of the European Hematology Association (“EHA”), to be held both virtually and in person from June 13 through 16, 2024.
  • The following abstracts were posted to the EHA website on May 14, 2024, 10:00 a.m. Eastern time.
  • “Durable clinical treatment with elritercept (KER-050) treatment: Findings from an ongoing Phase 2 trial in participants with lower-risk MDS”
    “Activin A Inhibition by elritercept (KER-050) is associated with evidence of cardiovascular benefit: Translation of preclinical observations to humans with MDS”
    “RKER-050, a modified activin receptor type IIA ligand trap, rescued anemia and increased muscle mass and strength in a mouse model of myelofibrosis”

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

Retrieved on: 
水曜日, 5月 8, 2024
Disorder, Protein, ATS, Investment, Pulmonary hypertension, Food, Research, Circulatory system, Conference, Orthostatic hypertension, KROS, Syndrome, Therapy, Patient, American Thoracic Society, Pharmaceutical industry

“Keros remained focused on clinical execution and continued to make strong progress across our pipeline in the first quarter of 2024,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer.

Key Points: 
  • “Keros remained focused on clinical execution and continued to make strong progress across our pipeline in the first quarter of 2024,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer.
  • General and administrative expenses were $10.3 million for the first quarter of 2024 as compared to $7.8 million for the same period in 2023.
  • Keros’ cash and cash equivalents as of March 31, 2024 was $442.4 million compared to $331.1 million as of December 31, 2023.
  • Keros expects that the cash and cash equivalents it had on hand at March 31, 2024 will enable Keros to fund its operating expenses and capital expenditure requirements into 2027.

Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

Retrieved on: 
木曜日, 3月 14, 2024
Anemia, Protein, MDS, KROS, Fast Track, Therapy, Patient, Disorder, FDA, Marketing, Food, Pharmaceutical industry

LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for KER-050 (elritercept) for the treatment of anemia in adult patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (“MDS”).

Key Points: 
  • LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for KER-050 (elritercept) for the treatment of anemia in adult patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (“MDS”).
  • “Receiving Fast Track designation for KER-050 underscores the need for novel treatment options to address the serious unmet medical needs of people living with lower-risk MDS,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer.
  • Programs with Fast Track designation can benefit from early and more frequent interactions with the FDA to discuss the product candidate’s development plan in addition to a rolling submission of the marketing application.
  • Product candidates with Fast Track designation may also be eligible for priority review and accelerated approval.

Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference

Retrieved on: 
火曜日, 3月 5, 2024
Protein, Therapy, Patient, SVB Securities, Disorder, Keros, KROS, Conference

LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Leerink Partners 2024 Global Biopharma Conference on Tuesday, March 12, 2024 at 3:00 p.m. Eastern time.

Key Points: 
  • LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Leerink Partners 2024 Global Biopharma Conference on Tuesday, March 12, 2024 at 3:00 p.m. Eastern time.
  • A live audio webcast of the fireside chat presentation will be available at https://wsw.com/webcast/leerink33/kros/2244432 and an archived replay will be accessible in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days following the conclusion of the event.

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
水曜日, 2月 28, 2024
Therapy, Research, Syndrome, Investment, Obesity, Technology transfer, Growth, KROS, PAH, Patient, Disorder, Protein, Ruxolitinib, Cytopenia, Orthostatic hypertension, Haematopoiesis, Keros, Pharmaceutical industry

Keros did not generate any revenue for the year ended December 31, 2022.

Key Points: 
  • Keros did not generate any revenue for the year ended December 31, 2022.
  • Research and development expenses were $37.5 million for the fourth quarter and $135.3 million for the year ended December 31, 2023, as compared to $24.9 million for the fourth quarter and $87.3 million for the year ended December 31, 2022.
  • General and administrative expenses were $9.1 million for the fourth quarter and $34.8 million for the year ended December 31, 2023, as compared to $7.1 million and $27.5 million for the fourth quarter and year ended December 31, 2022.
  • Keros’ cash and cash equivalents as of December 31, 2023 was $331.1 million compared to $279.0 million as of December 31, 2022.

Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress

Retrieved on: 
月曜日, 1月 29, 2024
Pulmonary Vascular Research Institute, Pulmonary hypertension, Therapy, KROS, Disorder, Patient, Treatment, Abstract, Protein, Pharmaceutical industry

LEXINGTON, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that three abstracts will be presented from the KER-012 program at the Pulmonary Vascular Research Institute (“PVRI”) 2024 Annual Congress, to be held from January 31 through February 3, 2024.

Key Points: 
  • LEXINGTON, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that three abstracts will be presented from the KER-012 program at the Pulmonary Vascular Research Institute (“PVRI”) 2024 Annual Congress, to be held from January 31 through February 3, 2024.
  • “Development of KER-012, a Novel Investigational Activin Receptor Type IIB Ligand Trap with High Activin/GDF Specificity and Target Engagement for the Treatment of Pulmonary Arterial Hypertension: Rationale and Design of the TROPOS Phase 2 Study”
    “RKER-012, A Novel Modified ActRIIB Ligand Trap, Reduced Pulmonary Vascular Pathology in a Rat Model of Pulmonary Arterial Hypertension”

Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock

Retrieved on: 
火曜日, 1月 9, 2024
Patient, Therapy, SVB Securities, Nicollet Mall, Prospectus, Form, Sale, Disorder, S-3, Protein, Telephone, Attention, KROS, Option, State Street, Exercise, Security (finance), File

The net proceeds to Keros from the offering, before deducting offering expenses, were approximately $151.3 million.

Key Points: 
  • The net proceeds to Keros from the offering, before deducting offering expenses, were approximately $151.3 million.
  • All of the common stock was offered by Keros.
  • Goldman Sachs & Co. LLC, Leerink Partners, Piper Sandler and Truist Securities acted as joint book-running managers for the offering.
  • A final prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC on January 4, 2024, and is available on the SEC’s website at www.sec.gov.

Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

Retrieved on: 
木曜日, 1月 4, 2024
Telephone, Protein, Sale, Nicollet Mall, Form, File, KROS, Attention, State Street, Therapy, SVB Securities, S-3, Prospectus, Patient, Truist, Security (finance), Disorder

The gross proceeds to Keros from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $140.0 million.

Key Points: 
  • The gross proceeds to Keros from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $140.0 million.
  • All of the common stock is being offered by Keros.
  • In addition, Keros has granted the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock at the public offering price, less the underwriting discounts and commissions.
  • Goldman Sachs & Co. LLC, Leerink Partners, Piper Sandler and Truist Securities are acting as joint book-running managers for the offering.

Keros Therapeutics Announces Proposed Public Offering of Common Stock

Retrieved on: 
水曜日, 1月 3, 2024
Telephone, Protein, Sale, Nicollet Mall, Form, File, KROS, Attention, State Street, Therapy, SVB Securities, S-3, Keros, Prospectus, Patient, Truist, Security (finance), Disorder

LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced the launch of a proposed underwritten public offering of $120.0 million of shares of its common stock (the “Offer Shares”).

Key Points: 
  • LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced the launch of a proposed underwritten public offering of $120.0 million of shares of its common stock (the “Offer Shares”).
  • All shares of common stock to be sold in the proposed offering will be sold by Keros.
  • The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Goldman Sachs & Co. LLC, Leerink Partners, Piper Sandler and Truist Securities are acting as joint book-running managers for the offering.